UK Medical Cannabis Patients 2025: Numbers and Demographics

UK Medical Cannabis Patients 2025: Numbers and Demographics

The landscape of medical cannabis UK has evolved significantly since the legalisation of cannabis-based products for medicinal use in November 2018. As we move through 2025, understanding the current patient population and demographic trends provides valuable insight into how medical cannabis is being accessed and used across the United Kingdom. This article explores available data on patient numbers, demographic patterns, and what these trends mean for those seeking treatment.

Current Patient Numbers and Access

Precise figures on the total number of medical cannabis patients in the UK remain difficult to establish due to fragmented data collection across NHS and private prescribing channels. However, according to reports from NHS England and the British Private Practitioners Association, the number of patients receiving medical cannabis prescriptions has grown steadily since 2019, though the absolute figure remains modest compared to many other medications.

Estimates suggest that between 10,000 and 15,000 patients across the UK may currently be in receipt of a medical cannabis prescription or have been approved for treatment. This figure includes patients prescribed through NHS hospital specialists, private medical professionals, and private clinics. The actual number likely represents only a fraction of those who might benefit from medical cannabis, given the strict criteria required for prescription and the continuing access barriers many patients face.

Private clinics have seen notable growth in patient numbers, particularly following the establishment of the Medical Cannabis Registry—a database designed to collect real-world evidence on medical cannabis use in the UK. Many patients seeking medical cannabis pursue private routes due to limited NHS availability, with estimated costs ranging from £1,000 to £3,000 per month depending on formulation and dosage requirements.

Age Demographics and Patient Profile

The demographic profile of UK medical cannabis patients has shown interesting patterns. Contrary to some assumptions, medical cannabis patients are not predominantly young adults, but rather spread across a broad age range. Data suggests that a significant proportion of patients are middle-aged or older, with many conditions treated occurring most commonly in those aged 40 and above.

Patients aged 18 to 65 represent the largest cohort seeking treatment, though increasing numbers of elderly patients (aged 65+) are now accessing medical cannabis, particularly for conditions such as chronic pain and neuropathic pain. Parents seeking medical cannabis for children with specific epileptic conditions represent another important demographic, though paediatric patient numbers remain relatively small due to the stringent requirements for treatment approval.

Gender distribution shows relatively balanced numbers between male and female patients, though certain conditions may skew this ratio. For example, women represent a higher proportion of patients seeking medical cannabis for conditions such as fibromyalgia and migraine, whilst men are more commonly treated for cancer-related pain and conditions like Crohn’s disease.

Condition-Based Patient Distribution

The range of conditions for which medical cannabis can be prescribed in the UK is defined by UK cannabis law and MHRA (Medicines and Healthcare products Regulatory Authority) guidance. The most common conditions among the current patient population include chronic pain, epilepsy (particularly treatment-resistant forms), multiple sclerosis, and chemotherapy-induced nausea and vomiting.

Chronic pain represents the single largest indication, accounting for an estimated 40-50% of all prescriptions. This includes patients with conditions such as fibromyalgia, neuropathic pain, and post-operative pain. Epilepsy patients, particularly those with treatment-resistant epilepsy, comprise approximately 15-20% of the patient population. Multiple sclerosis patients represent around 10-15% of the current patient base, whilst the remaining proportion includes those with other approved indications.

Notably, interest in medical cannabis extends beyond these primary indications, with patients seeking treatment for conditions including anxiety, Tourette’s syndrome, and various psychiatric conditions. However, the NICE guidelines and current regulatory framework limit prescription to specific evidence-based conditions, meaning that off-label use or treatment for unapproved conditions typically requires justification and specialist consultation.

Geographical Distribution and Regional Variation

Patient access to medical cannabis varies significantly across the UK’s constituent nations and regions. NHS provision remains inconsistent, with some areas having established specialist clinics whilst others have minimal access through NHS channels. Scotland, Wales, and Northern Ireland have each developed slightly different frameworks for patient access, though all operate within the overarching UK regulatory structure.

England’s NHS structure, with integrated care boards, has resulted in considerable variation in local access. Greater London, the South East, and parts of the East Midlands have generally seen higher patient numbers relative to population size, partly reflecting the concentration of private clinics in these areas. More rural regions face particular challenges, with patients often required to travel significant distances for specialist consultations.

The concentration of private clinics in major urban centres, particularly London, has created an accessibility divide between those with financial resources and geographic proximity to specialist services, and those in underserved areas. This geographic variation continues to influence patient demographics, with private clinic patient populations showing different characteristics from those accessing NHS services.

Future Projections and Emerging Trends

Looking ahead to the remainder of 2025 and beyond, several trends suggest potential changes in patient numbers and demographics. Increasing clinical evidence supporting medical cannabis for specific conditions may broaden eligibility criteria, potentially expanding the patient population. The development of NHS-approved pathways through services like the Medical Cannabis Registry continues to provide real-world evidence that may influence prescribing patterns.

Growing public awareness and improved understanding of the distinction between medical cannabis and recreational cannabis use are likely to increase patient enquiries. However, this will continue to be tempered by prescribing restrictions, cost barriers for private treatment, and the ongoing education needed among healthcare professionals regarding safe and effective use.

Demographic shifts may also occur as more elderly patients become aware of potential benefits, and as paediatric indications for specific epilepsy types continue to be refined. The patient population is likely to become increasingly diverse in terms of socioeconomic background, particularly if NHS access expands.

Frequently Asked Questions

How do I find out if I’m eligible for medical cannabis in 2025?

Eligibility depends on having a condition recognised by NICE guidelines or the MHRA. You should first speak with your GP or hospital specialist about whether medical cannabis might be appropriate for your condition. Your clinician can then refer you to a specialist for formal assessment. Some patients may choose to seek private consultation if NHS routes are unavailable in their area.

What is the difference between NHS and private medical cannabis prescriptions?

NHS prescriptions are available through hospital specialists for specific conditions and follow NICE guidance, though availability varies by region. Private prescriptions offer more flexibility and potentially faster access but require out-of-pocket payment (typically £1,000-£3,000 monthly). Both routes require proper medical assessment and follow-up.

Are there any demographic groups specifically underrepresented in the current patient population?

Yes. Certain groups including those in rural areas, ethnic minorities, and lower-income populations appear underrepresented in available data. This reflects barriers including geographic access, cost, awareness levels, and potential healthcare disparities. Efforts continue to improve equitable access across all demographic groups.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Medical cannabis is a prescription-only medicine in the UK. Always consult a qualified healthcare professional. CannaZen is an information platform, not a medical provider.